Medication info
JanuaTin Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

JanuaTin Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tablet
Manufacturer / importer
PharmGen Science Co., Ltd.
Appearance
Bright yellow-orange round film-coated tablets
Packaging
100 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202102457 · Approved 2021.03.19 · Insurance code 670105170

Summary

Main use
Improves blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medication is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medication and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
PharmGen Science Co., Ltd.

Efficacy & effects

Improves blood glucose control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This drug is used for patients with type 2 diabetes to improve blood sugar control along with dietary and exercise therapy. It can be administered alone, and if blood sugar control is difficult with monotherapy and no previous diabetes medications have been used, it may be combined with metformin. Additionally, this drug can be used in conjunction if blood sugar control is insufficient with sulfonylurea, metformin, thiazolidinedione, or insulin monotherapy. This drug is also added in combination if blood sugar control is difficult for patients using combinations of sulfonylurea and metformin, thiazolidinedione and metformin, or insulin and metformin. Ultimately, this medication helps to improve blood sugar control with various drug therapies.

How to take

Adult dose

This medication is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medication and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered without regard to the timing of dialysis.

Precautions

This drug can cause severe allergic reactions; if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a doctor. Additionally, inflammation of the pancreas may occur, so if abdominal pain, vomiting, or nausea occurs, visit a hospital immediately. This drug should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients with poor kidney function should adjust the dose of this drug and take it according to the physician's instructions. Hypoglycemia may occur during the use of this drug, especially when taken together with other diabetes medications such as insulin or sulfonylurea, so blood sugar levels should be monitored closely. Rarely, joint pain, skin rash, and vesicular skin diseases may occur; if these symptoms appear, inform a doctor and seek treatment. It is advisable for women who are pregnant or breastfeeding not to take this drug, and safety and efficacy have not been established in children under 18 years of age. Elderly patients may have reduced kidney function, so regular kidney function tests should be conducted before and during treatment. In case of overdose, general emergency treatment will be provided, and this drug can be removed via dialysis if necessary. This drug interacts minimally with other medications, but it should be discussed with a doctor when taking specific drugs.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory tract infection
  • headache
  • diarrhea
  • abdominal pain
Show 28 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to prevent air exposure and kept at a cool room temperature between 1 and 30 degrees Celsius. Storing it this way can help maintain the effectiveness of the medication for a long time.

Appearance and packaging

Appearance

Bright yellow-orange round film-coated tablets

Package unit

100 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.